Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 16:167:D6981.

[Lutetium-177-PSMA in metastasized prostate carcinoma]

[Article in Dutch]
Larissa W van Golen  1   2 , Wouter Vogel  1 , Marnix G E H Lam  3
Affiliations
  • PMID: 36943158

[Lutetium-177-PSMA in metastasized prostate carcinoma]

[Article in Dutch]
Larissa W van Golen et al. Ned Tijdschr Geneeskd. .

Abstract

Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.

PubMed Disclaimer

Publication types

MeSH terms